In this edition, Dr. Constance Thibault (FR), associate editor of the UROONCO PCa educational platform, discusses triplet therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).

In the last decade, the outcome of metastatic prostate cancer has been improved by intensifying the systemic therapy with the addition of docetaxel and/or new hormonal therapies. Clinicians now have several treatment options to offer their patients with mHSPC. This raises the issue of the optimal choice?

Dr. Thibault answers questions about why triplet therapy (ADT + DOCETAXEL + NHT) is recommended to mHSPC patients, and do all patients benefit from a triplet therapy or only specific subgroups?

Lastly, Dr. Thibault talks about which triplet therapy is recommended to use in clinical practice assuming that abiraterone and darolutamide are both approved in combination with ADT + DOCETAXEL for mHSPC patients.